At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Phase II Study of Nivolumab in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Nivolumab for Nasopharyngeal Nonkeratinizing Carcinoma and 6 related conditions. Completed, enrolled 45 participants across 19 sites in 3 countries.
Detailed Summary
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic). Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7
CountriesChina, Singapore, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartJul 2015
Primary CompletionJun 2018
TodayJul 2026
First PostedJan 15, 2015
Enrollment StartJul 21, 2015
Primary CompletionJun 16, 2018
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 11.5 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Nivolumabbiological
Given IV